secwatch.observer — SEC 8-K summary
======================================

Issuer:     uniQure N.V. (QURE)
CIK:        0001590560
Form:       8-K
Filed at:   2026-05-05T23:59:59+00:00
Accession:  0001104659-26-055242
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

uniQure Q1 net loss $53.5M ($0.85/share); AMT-130 UK MAA on track for Q3
------------------------------------------------------------------------

- Net loss of $53.5M vs $43.6M YoY; revenue $3.6M up from $1.6M on license revenue.
- Cash $586.6M; runway into H2 2029; R&D down 19% to $29.2M, SG&A up 84% to $20.1M.
- FDA Type B meeting scheduled Q2 2026 for AMT-130; UK MAA submission expected Q3 2026.
- AMT-260 cohort 2 enrollment on track mid-2026; data from first cohort at June 2026 conference.
- AMT-191 dosing paused at mid/high dose due to liver enzyme DLTs; all 11 patients off ERT.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590560/000110465926055242/0001104659-26-055242-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590560/000110465926055242/qure-20260505x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-055242

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer